Stoke Therapeutics Inc (STOK) Stock Price, Quote & News

Company Profile

Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational n...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 430 8200

Website: www.stoketherapeutics.com

Address:

45 Wiggins Avenue, Bedford, United States

MarketBeat May. 9 at 4:08 AM

Stoke Therapeutics Q1 Earnings Call Highlights $STOK https://www.marketbeat.com/instant-alerts/stoke-therapeutics-q1-earnings-call-highligh

0 · Reply

LadsAndGents May. 5 at 3:30 PM

$STOK please go to 24 former load back again

0 · Reply

Doozio May. 4 at 2:33 PM

$XBI ACSM BODI n they wud say DRUG $STOK s will start gapping right on $CUE

0 · Reply

GorillaTrades Apr. 17 at 7:03 PM

Top 3 #momentum #stocks In The GorillaTrades #portfolio This Week: Stoke Therapeutics $STOK +6.6%, NVIDIA $NVDA +6.5%, and Celcuity $CELC +4.6%

0 · Reply

GorillaTrades Apr. 10 at 7:37 PM

Top 3 #momentum #stocks In The GorillaTrades #portfolio This Week: Stoke Therapeutics $STOK +6.7%, Celcuity $CELC +3.6%, and Cincinnati Financial $CINF +2.5%

0 · Reply

Doozio Apr. 10 at 1:05 AM

$IWM $SMH $XBI how long until they go from fear to walking ENTA da weekend chasing $STTK s and $STOK s.

0 · Reply

NorthStarStats Apr. 8 at 8:39 PM

Output from a custom NorthStarStats momentum scanner highlighting stocks with strengthening price structure and momentum. Setups to watch and study — not trade recommendations. $FRT Score 100, $ANET Score 98, $ENTG Score 98, $STOK Score 98, $ASND Score 98

0 · Reply

Doozio Mar. 31 at 2:01 PM

$XBI list of biotech $STOK s that $AUPH to $ASND after this 🐑 correction.

0 · Reply

StocktwitsEarnings Mar. 26 at 7:00 PM

$STOK Q4 '25 Earnings Results & Recap Stoke Therapeutics expects its cash, cash equivalents, and marketable securities of approximately $390.9M as of December 31, 2025, will fund operations into 2028, and anticipates pivotal Phase 3 data for zorevunersen in mid-2027.

0 · Reply